April 16, 2020
Gilead Sciences is poised to seek an early submission in Japan for its investigational antiviral remdesivir for the treatment of COVID-19 if it can confirm the drug’s safety and efficacy in initial trial data covering 1,000 people, Masa Omote, head...read more